发明名称 |
Identification of Biomarkers Predictive of Dasatinib Effects in Cancer Cells |
摘要 |
A method of predicting response to treatment with inhibitors of EGFR and SRC by screening for status of key biomarkers such as EGFR. Dasatinib is a drug that can inhibit a group of proteins called SRC proteins. In addition, other experiments have suggested that other important signaling proteins are affected by dasatinib. Early phase trials of dasatinib are ongoing in cancer patients. It will be important to determine which patients receive a clinical benefit of dasatinib. Predetermination of treatment benefit can be performed by assessing biomarkers in patients tumors prior to treatment with dasatinib or other inhibitors of EGFR and SRC. Patients that have positive biomarkers for treatment could then be treated with higher confidence of benefit while those not possessing these predictive biomarkers would avoid ineffective and potentially toxic therapy. Additionally, treatment can be tailored according to predetermined sensitivity by evaluating indicated biomarkers correlating with sensitivity to one or more agents. |
申请公布号 |
US2010004257(A1) |
申请公布日期 |
2010.01.07 |
申请号 |
US20090501897 |
申请日期 |
2009.07.13 |
申请人 |
UNIVERSITY OF SOUTH FLORIA |
发明人 |
HAURA ERIC BRUCE |
分类号 |
A61K31/506;A61P35/00;A61P35/02 |
主分类号 |
A61K31/506 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|